• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2021 年 4 月，在英国伦敦，一家养老院在部分接种了一剂 COVID-19 疫苗 Vaxzevria 后，由 SARS-CoV-2 Delta（B.1.617.2）变异株引发的疫情。

An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.

机构信息

National Infection Service, Public Health England, London, United Kingdom.

London Coronavirus Response Centre, Public Health England, London, United Kingdom.

出版信息

Euro Surveill. 2021 Jul;26(27). doi: 10.2807/1560-7917.ES.2021.26.27.2100626.

DOI:10.2807/1560-7917.ES.2021.26.27.2100626
PMID:34240699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8268653/
Abstract

We investigated a COVID-19 outbreak of the SARS-CoV-2 Delta variant of concern in a London care home, where 8/21 residents and 14/21 staff had received a single dose of Vaxzevria (ChAdOx1-S; AstraZeneca) vaccine. We identified 24 SARS-CoV-2 infections (16 residents, 8 staff) among 40 individuals (19 residents, 21 staff); four (3 residents, 1 staff) were hospitalised, and none died. The attack rate after one vaccine dose was 35.7% (5/14) for staff and 81.3% (13/16) for residents.

摘要

我们调查了伦敦一家养老院中关注的 SARS-CoV-2 德尔塔变异株的 COVID-19 爆发，其中 21 名居民中有 8 人，21 名员工中有 14 人接受了一剂 Vaxzevria（ChAdOx1-S；阿斯利康）疫苗。我们在 40 人中发现了 24 例 SARS-CoV-2 感染（16 名居民，8 名员工）；4 人（3 名居民，1 名员工）住院，无人死亡。一剂疫苗接种后的发病率为员工的 35.7%（5/14），居民的 81.3%（13/16）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebc/8268653/37faa8e35f01/2100626-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebc/8268653/37faa8e35f01/2100626-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ebc/8268653/37faa8e35f01/2100626-f1.jpg

相似文献

1
An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.2021 年 4 月，在英国伦敦，一家养老院在部分接种了一剂 COVID-19 疫苗 Vaxzevria 后，由 SARS-CoV-2 Delta（B.1.617.2）变异株引发的疫情。
Euro Surveill. 2021 Jul;26(27). doi: 10.2807/1560-7917.ES.2021.26.27.2100626.
2
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性（VIVALDI）：一项前瞻性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.
3
A natural experiment during lockdown and on-going care-home COVID-19 outbreaks showed a single dose of vaccine reduced hospitalisation and deaths of care-home residents in North West England.在封锁期间和持续的养老院 COVID-19 爆发期间进行的一项自然实验表明，在英格兰西北部，一剂疫苗可降低养老院居民的住院率和死亡率。
Public Health. 2024 Aug;233:60-64. doi: 10.1016/j.puhe.2024.05.002. Epub 2024 Jun 7.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
5
A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine.mRNA COVID-19 疫苗加强针接种后，养老院居民中出现 SARS-CoV-2 疫情。
J Community Health. 2022 Aug;47(4):598-603. doi: 10.1007/s10900-022-01082-8. Epub 2022 Mar 25.
6
A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID-19 during a SARS-coronavirus-2 outbreak in a senior citizen home in Germany.一剂辉瑞/BioNTech 公司的 BNT162b2 疫苗可预防德国一家养老院在 SARS-CoV-2 爆发期间老年人发生重症 COVID-19。
Immun Inflamm Dis. 2021 Dec;9(4):1809-1814. doi: 10.1002/iid3.532. Epub 2021 Sep 16.
7
An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward.一起德尔塔变异株引起的精神科封闭病房突破性感染事件
J Korean Med Sci. 2022 Jan 24;37(4):e28. doi: 10.3346/jkms.2022.37.e28.
8
Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.mRNA 抗 COVID-19 疫苗两剂接种 28 周后养老院发生的 SARS-CoV-2 B.1.617.2（德尔塔）变异株爆发：免疫效力下降的证据。
Clin Microbiol Infect. 2022 Apr;28(4):614.e5-614.e7. doi: 10.1016/j.cmi.2021.12.013. Epub 2021 Dec 24.
9
Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.mRNA BNT162b2 新冠疫苗在法国南部长期护理机构老年居民中预防 SARS-CoV-2 德尔塔变异株的有效性，2021 年 5 月。
Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2586-2591. doi: 10.26355/eurrev_202204_28496.
10
High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023.2023 年 8 月，英格兰东部一家大型养老院发生的 SARS-CoV-2 BA.2.86 疫情高感染率。
Euro Surveill. 2023 Sep;28(39). doi: 10.2807/1560-7917.ES.2023.28.39.2300489.

引用本文的文献

1
Acceptance for a booster dose of COVID-19 vaccine in Indonesia: A follow-up study.印度尼西亚民众对新冠疫苗加强针的接受度：一项随访研究。
Narra J. 2025 Apr;5(1):e803. doi: 10.52225/narra.v5i1.803. Epub 2025 Feb 13.
2
Comparative Analysis of COVID-19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study.三级医疗中心德尔塔变异株激增期间接种疫苗与未接种疫苗个体的新冠严重程度和死亡率比较分析：一项队列研究
Health Sci Rep. 2025 Jan 16;8(1):e70346. doi: 10.1002/hsr2.70346. eCollection 2025 Jan.
3
Description of control measures, attitudes, and behaviours at a scientific conference with a confirmed COVID-19 case but no reported onward transmission, November 2021 England.

本文引用的文献

1
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
2
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性（VIVALDI）：一项前瞻性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.
3
2021年11月英国一场科学会议的防控措施、态度及行为描述，该会议出现一例确诊的新冠病毒病病例，但无后续传播报告。
Public Health Pract (Oxf). 2024 Jun 20;8:100521. doi: 10.1016/j.puhip.2024.100521. eCollection 2024 Dec.
4
Epidemiology of COVID-19 outbreaks in aged care facilities during postvaccine period: a systematic review and meta-analysis.疫苗接种后老年护理机构中 COVID-19 疫情的流行病学：系统评价和荟萃分析。
BMJ Open. 2024 Mar 14;14(3):e073555. doi: 10.1136/bmjopen-2023-073555.
5
Transmission chains of the first local outbreak cause by Delta VariantB.1.617.2 COVID-19 in Guangzhou, Southern China.中国南方广州首次由 Delta 变异株 B.1.617.2 引起的本地疫情传播链。
BMC Infect Dis. 2024 Jan 2;24(1):24. doi: 10.1186/s12879-023-08819-3.
6
High attack rate in a large care home outbreak of SARS-CoV-2 BA.2.86, East of England, August 2023.2023 年 8 月，英格兰东部一家大型养老院发生的 SARS-CoV-2 BA.2.86 疫情高感染率。
Euro Surveill. 2023 Sep;28(39). doi: 10.2807/1560-7917.ES.2023.28.39.2300489.
7
A Molecular and Epidemiological Investigation of a Large SARS-CoV-2 Outbreak in a Long-Term Care Facility in Luxembourg, 2021.2021年卢森堡一家长期护理机构中大规模新冠病毒（SARS-CoV-2）疫情的分子与流行病学调查
Geriatrics (Basel). 2023 Jan 26;8(1):19. doi: 10.3390/geriatrics8010019.
8
CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy.CLEC5A 的表达可被刺突糖蛋白触发，可能成为 COVID-19 治疗的潜在靶点。
J Med Virol. 2023 Jan;95(1):e28427. doi: 10.1002/jmv.28427.
9
Willingness to Pay (WTP) for COVID-19 Vaccine Booster Dose and Its Determinants in Indonesia.印度尼西亚民众对新冠疫苗加强针的支付意愿及其影响因素
Infect Dis Rep. 2022 Dec 11;14(6):1017-1032. doi: 10.3390/idr14060101.
10
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.基于白蛋白-血管紧张素转换酶 2 的 SARS-CoV-2 诱饵，具有 FcRn 驱动的半衰期延长作用。
Acta Biomater. 2022 Nov;153:411-418. doi: 10.1016/j.actbio.2022.09.048. Epub 2022 Sep 24.
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
辉瑞-生物科技疫苗和牛津-阿斯利康疫苗对英格兰老年人新冠病毒相关症状、住院及死亡率的有效性：检测阴性病例对照研究
BMJ. 2021 May 13;373:n1088. doi: 10.1136/bmj.n1088.
4
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Asymptomatic SARS-CoV-2 Infection and COVID-19 Mortality During an Outbreak Investigation in a Skilled Nursing Facility.在一家熟练护理机构的暴发调查中，无症状 SARS-CoV-2 感染和 COVID-19 死亡率。
Clin Infect Dis. 2020 Dec 31;71(11):2920-2926. doi: 10.1093/cid/ciaa763.
7
Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.华盛顿州金县长期护理机构中 COVID-19 的流行病学。
N Engl J Med. 2020 May 21;382(21):2005-2011. doi: 10.1056/NEJMoa2005412. Epub 2020 Mar 27.